Jarcohix 50 Tablet contains Vildagliptin 50 mg, an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus. Vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the levels of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner. This mechanism helps improve glycemic control without causing significant hypoglycemia. Jarcohix 50 is indicated as monotherapy in patients inadequately controlled by diet and exercise alone, or as combination therapy with other antidiabetic agents such as metformin, sulfonylureas, or insulin. The recommended dosage is one tablet daily, which may be adjusted based on the patient’s glycemic response and tolerability. Jarcohix 50 should be used with caution in patients with renal impairment, and dose adjustments may be necessary. Common adverse effects include headache, dizziness, and gastrointestinal disturbances, while rare but serious side effects such as pancreatitis have been reported. Regular monitoring of blood glucose levels and renal function is advised during therapy. Jarcohix 50 should be prescribed as part of a comprehensive diabetes management plan including diet, exercise, and lifestyle modifications.